BRPI0418634A - composição farmacêutica combinada para a inibição do declìnio das funções cognitivas - Google Patents

composição farmacêutica combinada para a inibição do declìnio das funções cognitivas

Info

Publication number
BRPI0418634A
BRPI0418634A BRPI0418634-6A BRPI0418634A BRPI0418634A BR PI0418634 A BRPI0418634 A BR PI0418634A BR PI0418634 A BRPI0418634 A BR PI0418634A BR PI0418634 A BRPI0418634 A BR PI0418634A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
decline
combined pharmaceutical
syndrome
inhibition
Prior art date
Application number
BRPI0418634-6A
Other languages
English (en)
Inventor
Gyoergy Levay
Istvan Gacsalyi
Laszlo Gabor Harsing
Gyula Simig
Original Assignee
Egis Gyogyszergyar Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Gyogyszergyar Nyrt filed Critical Egis Gyogyszergyar Nyrt
Publication of BRPI0418634A publication Critical patent/BRPI0418634A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

COMPOSIçãO FARMACêUTICA COMBINADA PARA A INIBIçãO DO DECLìNIO DAS FUNçõES COGNITIVAS A invenção se refere-se a uma composição farmacêutica combinada para a inibição do declínio das funções congnitivas, compreendendo, como componente A), (1R, 2S, 4R) - (-) -2 - ¢N,N- (dimetilaminoetóxil)! - 2- fenil - 1,7,7-trimetilbiciclo ¢2.21! hepano de fórmula (I) o seu sal de adição de ácido farmaceuticamente aceitável e, como componente B), um nootrópico, um inibidor da enzima acetilcolinesterase e/ou um ingrediente ativo farmacêutico adicional que exiba um efeito benéficio sobre os processos congnitivos, em mistrura com veículos farmacêuticos inertes adequados e/ou agentes auxliliares. A composição farmacêutica combinada de acordo com a presente invenção pode ser particularmente usada para o taratamento de doença de Alzheimer ou outras doenças que mostrem sintomas similares, doenças de disfunções das capacidades intelectuais (por exemplo, declínio mental na esquizofrenia), declínio mental nos idosos (demências dos idosos), sínrome de korsakoff, síndrome de Huntington, síndrome de parkinson ou declínio mental produzido pelo alcoolismo.
BRPI0418634-6A 2004-03-12 2004-03-12 composição farmacêutica combinada para a inibição do declìnio das funções cognitivas BRPI0418634A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/HU2004/000022 WO2005087212A1 (en) 2004-03-12 2004-03-12 Combined pharmaceutical composition for the inhibition of the decline of cognitive functions

Publications (1)

Publication Number Publication Date
BRPI0418634A true BRPI0418634A (pt) 2007-05-29

Family

ID=34957271

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418634-6A BRPI0418634A (pt) 2004-03-12 2004-03-12 composição farmacêutica combinada para a inibição do declìnio das funções cognitivas

Country Status (17)

Country Link
US (1) US20080021016A1 (pt)
EP (1) EP1727531A1 (pt)
JP (1) JP2007528892A (pt)
CN (1) CN1925849A (pt)
AU (1) AU2004317129A1 (pt)
BR (1) BRPI0418634A (pt)
CA (1) CA2559493A1 (pt)
CZ (1) CZ2006628A3 (pt)
EA (1) EA200601666A1 (pt)
HR (1) HRP20060326A2 (pt)
IL (1) IL177735A0 (pt)
IS (1) IS8547A (pt)
MX (1) MXPA06010384A (pt)
NO (1) NO20064644L (pt)
RS (1) RS20060505A (pt)
SK (1) SK50802006A3 (pt)
WO (1) WO2005087212A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010278711A1 (en) 2009-07-31 2012-02-23 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
CN104173336B (zh) * 2010-03-31 2018-02-02 重庆润泽医药有限公司 左旋奥拉西坦在制备预防或治疗认知功能障碍药物中的应用
CN103458885B (zh) 2011-02-02 2016-02-10 考格尼申治疗股份有限公司 由姜黄油分离的化合物及使用方法
ITGE20110050A1 (it) * 2011-04-29 2012-10-30 Marco Zipoli Alimento, in particolare una bevanda per l'alimentazione umana
ES2915833T3 (es) 2014-01-31 2022-06-27 Cognition Therapeutics Inc Composiciones de isoindolina y métodos para tratar una enfermedad neurodegenerativa y una degeneración macular
EP3634394A4 (en) 2017-05-15 2021-04-07 Cognition Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
DE4136288A1 (de) * 1991-11-04 1993-05-06 Troponwerke Gmbh & Co Kg, 5000 Koeln, De Kombination von calciumantagonisten mit cholinesterase-inhibitoren
DK0813411T3 (da) * 1995-02-15 2002-05-13 Takeda Chemical Industries Ltd Anvendelse af vincopetinderivater til hæmning af dannelse eller afsondring af amyloid -protein
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
GB9820489D0 (en) * 1998-09-22 1998-11-11 Steiger Malcolm J Compounds for improved treatment of parkinson's disease
US6426097B2 (en) * 2000-01-28 2002-07-30 Herbaceuticals Inc. Herbal supplement for cognitive related impairment due to estrogen loss
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
BR0108823A (pt) * 2000-12-29 2002-12-10 Osmotica Corp Composição farmacêutica para o tratamento da doença cerebrovascular cognitiva
HUP0103017A3 (en) * 2001-07-18 2004-05-28 Egis Gyogyszergyar Nyilvanosan Pharmaceutical composition for the treatment of diseases caused by impairment of cognitive functions and its use
WO2003020289A1 (en) * 2001-08-30 2003-03-13 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
DE20203244U1 (de) * 2002-03-01 2002-05-23 Meins Wolfgang Pharmazeutische Zusammensetzung zur Prävention der Alzheimerdemenz
CN100337628C (zh) * 2002-08-07 2007-09-19 王登之 治疗痴呆症的尼莫地平口腔崩解片及其制备方法

Also Published As

Publication number Publication date
IL177735A0 (en) 2006-12-31
EP1727531A1 (en) 2006-12-06
NO20064644L (no) 2006-12-11
CA2559493A1 (en) 2005-09-22
AU2004317129A1 (en) 2005-09-22
SK50802006A3 (sk) 2007-03-01
HRP20060326A2 (en) 2007-02-28
WO2005087212A1 (en) 2005-09-22
IS8547A (is) 2006-10-03
MXPA06010384A (es) 2007-03-07
CZ2006628A3 (cs) 2007-01-24
US20080021016A1 (en) 2008-01-24
JP2007528892A (ja) 2007-10-18
EA200601666A1 (ru) 2007-04-27
RS20060505A (en) 2008-09-29
CN1925849A (zh) 2007-03-07

Similar Documents

Publication Publication Date Title
BRPI0608205B8 (pt) derivado heterocíclico-1-carboxilato de piridila não-aromático nitrogenado, composição farmacêutica e uso do dito composto para o tratamento de frequência urinária, incontinência urinária, bexiga hiperativa e dor
BR0210267A (pt) Composição farmacêutica sólida, processo para preparar a mesma, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases
TR201820559T4 (tr) Azelastin içeren kompozisyonlar ve bunların kullanım metotları.
BR0314299A (pt) Derivados de pirrolidona como inibidores de mao-b
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
BR0211807A (pt) Derivados ativos amino-ftalazinona como inibidores de cinase, processo para sua preparação e composições farmacêuticas para os mesmos
BR0211742A (pt) Derivados de aminoisoxazole ativos como inibidores de cinase
BR0312232A (pt) Inibidores de caspases e seus usos
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BRPI0416989A (pt) derivados aminopirazole como inibidores gsk-3
BR0209821A (pt) Compostos, processo para a manufatura desses compostos, composições farmacêuticas que compreendem os mesmos, processo para o tratamento e/ou profilaxia de enfermidades e utilização dos compostos
BRPI0507041A (pt) composto derivados de sulfonamida para o tratamento de doenças seus usos, processo para a preparação dos compostos e combinação de compostos
BR0314071A (pt) Derivados de pró-droga de 1,3-diamino-2-hidroxipropano
BR112013019955A2 (pt) n-[3-(5-amino-3,3a,7,7a-tetra-hidro-1h-2,4-dioxa-6-aza-inden-7-il)-fenil]-amidas como inibidores de bace1 e/ou de bace2
BRPI0615690B8 (pt) compostos heterocíclicos de hidroxamato, seus usos e composição farmacêutica
BR112014006763A2 (pt) n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1
BRPI0410660A (pt) derivados de 2-amino-piridina como agonistas de adrenoreceptor ß2
BRPI0519351A2 (pt) medicamentos para o tratamento ou prevenÇço de doenÇas fibràticas
BR112022011951A2 (pt) Tratamento de esclerose lateral amiotrófica e distúrbios relacionados
BR0014946A (pt) Uso de dipiridamol ou mopidamol na fabricação de um medicamento para o tratamento e prevenção de distúrbios da microcirculação dependentes da fibrina
AR040928A1 (es) Compuestos de acidos sulfona-hidroxamicos aromaticos, composiciones farmaceuticas y su uso en la preparacion de medicamentos utiles como inhibidores de proteasas
HRP20060326A2 (en) Combined pharmaceutical composition for the inhibition of the decline of cognitive functions
BRPI0409818A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
ES2295435T3 (es) Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento del fallo cognitivo.
BRPI0409878A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 3A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.